We evaluated 105 patients with nonalcoholic fatty liver disease ( NAFLD ) , 121 patients with biopsy-proven hepatitis C ( 61 patients with fatty liver and 60 patients without fatty liver ) , 50 patients with inflammatory bowel disease ( IBD ) , and 109 patients with dyspepsia .